- Home
- TORO vs ACET Comparison
TORO vs ACET Comparison
Compare TORO & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TORO
- ACET
- Stock Information
- Founded
- TORO 2022
- ACET 1947
- Country
- TORO Cyprus
- ACET United States
- Employees
- TORO N/A
- ACET N/A
- Industry
- TORO Marine Transportation
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- TORO Consumer Discretionary
- ACET Health Care
- Exchange
- TORO Nasdaq
- ACET Nasdaq
- Market Cap
- TORO 78.4M
- ACET 69.9M
- IPO Year
- TORO N/A
- ACET N/A
- Fundamental
- Price
- TORO $4.04
- ACET $0.89
- Analyst Decision
- TORO
- ACET Buy
- Analyst Count
- TORO 0
- ACET 4
- Target Price
- TORO N/A
- ACET $6.00
- AVG Volume (30 Days)
- TORO 195.4K
- ACET 2.9M
- Earning Date
- TORO 11-11-2025
- ACET 11-06-2025
- Dividend Yield
- TORO N/A
- ACET N/A
- EPS Growth
- TORO N/A
- ACET N/A
- EPS
- TORO 0.01
- ACET N/A
- Revenue
- TORO $20,143,992.00
- ACET N/A
- Revenue This Year
- TORO N/A
- ACET N/A
- Revenue Next Year
- TORO N/A
- ACET N/A
- P/E Ratio
- TORO $309.50
- ACET N/A
- Revenue Growth
- TORO 0.40
- ACET N/A
- 52 Week Low
- TORO $1.70
- ACET $0.45
- 52 Week High
- TORO $4.94
- ACET $1.48
- Technical
- Relative Strength Index (RSI)
- TORO 60.79
- ACET 49.86
- Support Level
- TORO $3.84
- ACET $0.86
- Resistance Level
- TORO $4.19
- ACET $1.07
- Average True Range (ATR)
- TORO 0.18
- ACET 0.10
- MACD
- TORO -0.05
- ACET -0.01
- Stochastic Oscillator
- TORO 27.78
- ACET 32.80
About TORO Toro Corp.
Toro Corp acquires, owns, charters, and operates oceangoing tanker vessels and provides seaborne transportation services for crude oil and refined petroleum products. It operates in three reportable segments: the Aframax tanker, the LPG carrier segment, and the Handysize tanker. The company generates maximum revenue from the Aframax tanker segment.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.